{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:20:32Z","timestamp":1791109232150,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1016\/j.clim.2009.05.007","type":"journal-article","created":{"date-parts":[[2009,6,10]],"date-time":"2009-06-10T13:06:11Z","timestamp":1244639171000},"page":"334-341","source":"Crossref","is-referenced-by-count":85,"title":["Immunogenicity of rituximab in patients with severe pemphigus"],"prefix":"10.1016","volume":"132","author":[{"given":"Enno","family":"Schmidt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Hennig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Mengede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Detlef","family":"Zillikens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arno","family":"Kromminga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2009.05.007_bib1","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMra061111","article-title":"Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome","volume":"355","author":"Stanley","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2009.05.007_bib2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.0906-6705.2006.00410.x","article-title":"Cholinergic control of epidermal cohesion","volume":"15","author":"Grando","year":"2006","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.clim.2009.05.007_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006263.pub2","article-title":"Interventions for pemphigus vulgaris and pemphigus foliaceus","volume":"1","author":"Martin","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.clim.2009.05.007_bib4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(05)66829-8","article-title":"Pemphigus","volume":"366","author":"Bystryn","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2009.05.007_bib5","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/j.1365-2133.2003.05665.x","article-title":"Guidelines for the management of pemphigus vulgaris","volume":"149","author":"Harman","year":"2003","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.clim.2009.05.007_bib6","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s12016-007-8021-6","article-title":"Rituximab in treatment-resistant autoimmune blistering skin disorders","volume":"34","author":"Schmidt","year":"2008","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.clim.2009.05.007_bib7","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1586\/17469872.3.3.259","article-title":"CD20-directed therapy in autoimmune diseases involving the skin: role of rituximab","volume":"3","author":"Schmidt","year":"2008","journal-title":"Expert Rev. Dermatol."},{"key":"10.1016\/j.clim.2009.05.007_bib8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.intimp.2008.10.004","article-title":"A review of the current use of rituximab in autoimmune diseases","volume":"9","author":"Gurcan","year":"2009","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.clim.2009.05.007_bib9","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJM198205203062001","article-title":"Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease","volume":"306","author":"Anhalt","year":"1982","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2009.05.007_bib10","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1056\/NEJMoa062930","article-title":"Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin","volume":"355","author":"Ahmed","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2009.05.007_bib11","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa067752","article-title":"A single cycle of rituximab for the treatment of severe pemphigus","volume":"357","author":"Joly","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2009.05.007_bib12","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2133.2006.07646.x","article-title":"Rituximab in autoimmune bullous diseases: mixed responses and adverse effects","volume":"156","author":"Schmidt","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.clim.2009.05.007_bib13","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1365-2133.2007.08358.x","article-title":"Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins","volume":"158","author":"Shimanovich","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.clim.2009.05.007_bib14","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1365-2230.1991.tb00336.x","article-title":"Chronic bullous dermatosis of childhood\u2014clinical and immunological features seen in African patients","volume":"16","author":"Aboobaker","year":"1991","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.clim.2009.05.007_bib15","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.intimp.2004.04.015","article-title":"Rituximab-mediated depletion of cynomolgus monkey B cells in vitro in different matrices: possible inhibitory effect of IgG","volume":"4","author":"Vugmeyster","year":"2004","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.clim.2009.05.007_bib16","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/art.21617","article-title":"Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis","volume":"54","author":"Leandro","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2009.05.007_bib17","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1002\/art.20592","article-title":"Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus","volume":"50","author":"Anolik","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2009.05.007_bib18","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1038\/jid.2008.178","article-title":"B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses","volume":"128","author":"Mouquet","year":"2008","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.clim.2009.05.007_bib19","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nrd2085","article-title":"B cells move to centre stage: novel opportunities for autoimmune disease treatment","volume":"5","author":"Browning","year":"2006","journal-title":"Nat. Rev., Drug Discov."},{"key":"10.1016\/j.clim.2009.05.007_bib20","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2002-06-1639","article-title":"Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance","volume":"101","author":"Manshouri","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clim.2009.05.007_bib21","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1136\/ard.2007.083162","article-title":"Variability in the biological response to anti-CD20 B-cell depletion in SLE","volume":"67","author":"Albert","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2009.05.007_bib22","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2009.05.007_bib23","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/art.20430","article-title":"B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab","volume":"50","author":"Looney","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2009.05.007_bib24","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clim.2009.05.007_bib25","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/art.21260","article-title":"Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study","volume":"52","author":"Pijpe","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2009.05.007_bib26","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1002\/art.22046","article-title":"Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment","volume":"54","author":"Smith","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2009.05.007_bib27","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10165-007-0565-z","article-title":"A multicenter phase I\/II trial of rituximab for refractory systemic lupus erythematosus","volume":"17","author":"Tanaka","year":"2007","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.clim.2009.05.007_bib28","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clim.2009.05.007_bib29","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jim.2007.06.011","article-title":"Evaluation of a peptide ELISA for the detection of rituximab in serum","volume":"325","author":"Blasco","year":"2007","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.clim.2009.05.007_bib30","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jim.2007.07.004","article-title":"An Affinity Capture Elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug","volume":"327","author":"Bourdage","year":"2007","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.clim.2009.05.007_bib31","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1023\/A:1008389119525","article-title":"Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma","volume":"10","author":"Piro","year":"1999","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.clim.2009.05.007_bib32","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4049\/jimmunol.177.1.362","article-title":"The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20","volume":"177","author":"Teeling","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2009.05.007_bib33","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jim.2004.03.012","article-title":"Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas","volume":"289","author":"Beum","year":"2004","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.clim.2009.05.007_bib34","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jim.2004.09.003","article-title":"Simple quantitative live cell and anti-idiotypic antibody based ELISA for humanized antibody directed to cell surface protein CD20","volume":"294","author":"Hong","year":"2004","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.clim.2009.05.007_bib35","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1182\/blood-2004-05-1733","article-title":"A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells","volume":"104","author":"Cragg","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clim.2009.05.007_bib36","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.critrevonc.2006.09.004","article-title":"Pharmacokinetics of rituximab and its clinical use: thought for the best use?","volume":"62","author":"Cartron","year":"2007","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.clim.2009.05.007_bib37","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/rheumatology\/kei075","article-title":"Extremely high titer of anti-human chimeric antibody following re-treatment with rituximab in a patient with active systemic lupus erythematosus","volume":"44","author":"Saito","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clim.2009.05.007_bib38","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":", Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2009.05.007_bib39","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMoa074943","article-title":"Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose","volume":"358","author":"Chung","year":"2008","journal-title":"N. Engl. J. Med."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661609006688?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661609006688?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T13:18:10Z","timestamp":1589894290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661609006688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S1521661609006688"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2009.05.007","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}